Takeda Pharmaceutical Li... (TAK)
NYSE: TAK
· Real-Time Price · USD
15.10
-0.24 (-1.56%)
At close: Sep 12, 2025, 3:59 PM
15.20
0.66%
After-hours: Sep 12, 2025, 05:57 PM EDT
-1.56% (1D)
| Bid | 14.98 |
| Market Cap | 47.69B |
| Revenue (ttm) | 4,480.2B |
| Net Income (ttm) | 136.88B |
| EPS (ttm) | 0.29 |
| PE Ratio (ttm) | 52.07 |
| Forward PE | 0.19 |
| Analyst | n/a |
| Ask | 15.5 |
| Volume | 2,657,050 |
| Avg. Volume (20D) | 3,698,454 |
| Open | 15.20 |
| Previous Close | 15.34 |
| Day's Range | 15.03 - 15.20 |
| 52-Week Range | 12.80 - 15.69 |
| Beta | 0.27 |
Next Earnings Release
Takeda Pharmaceutical Limited is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-5.25%
Takeda Pharmaceutical shares are trading lower fol...
Unlock content with
Pro Subscription
6 months ago
+2.98%
Takeda Pharmaceutical shares are trading higher after the company announced topline results from phase 3 verify study of rusfertide in patients with polycythemia vera.
2 days ago · businesswire.com
Takeda Appoints Rhonda Pacheco President of the U.S. Business UnitCAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, eff...
